Targets › BCR
22 programs from 19 companies in 95 trials: 53 Phase 2, 26 Phase 1, 14 Phase 3, 2 Phase 4; Oncology, Other, Neurology; next expected readout Dec 2026.
Protein with a unique structure having two opposing regulatory activities toward small GTP-binding proteins. The C-terminus is a GTPase-activating protein (GAP) domain which stimulates GTP hydrolysis by RAC1, RAC2 and CDC42. (UniProt, P11274)
Open in Phaseline: the race on BCR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Novartis | Asciminib Tyrosine-protein kinase ABL inhibitor; Bcr/Abl fusion protein inhibitor | ABL1, BCR | Phase 4 | Chronic Myelogenous Leukemia; Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive; Philadelphia Chromosome-Positive Chronic Myeloid Leukemia; Chronic Myelogenous Leukemia - Chronic Phase … | Sep 2027 |
| National Cancer Institute (NCI) | Dasatinib Bcr/Abl fusion protein inhibitor | ABL1, BCR | Phase 3 | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1; Acute Lymphoblastic Leukemia; Chronic Myeloid Leukemia, BCR-ABL1 Positive; B Acute Lymphoblastic Leukemia … | Jan 2027 |
| Ascentage Pharma Group | Olverembatinib Bcr/Abl fusion protein inhibitor | ABL1, BCR | Phase 3 | GIST; Chronic Myeloid Leukemia; Ph+ ALL; Pharmacokinetic … | Mar 2027 |
| Il-Yang Pharm. | Radotinib Bcr/Abl fusion protein inhibitor | ABL1, BCR | Phase 3 | Chronic Myeloid Leukemia, Chronic Phase; Parkinson Disease | Apr 2027 |
| Takeda | Ponatinib Bcr/Abl fusion protein inhibitor | ABL1, BCR | Phase 3 | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL); Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive); B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative; Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive … | Jul 2027 |
| National Cancer Institute (NCI) | Imatinib Mesylate Tyrosine-protein kinase ABL inhibitor; Platelet-derived growth factor receptor beta inhibitor; Stem cell growth factor receptor inhibitor | ABL1, PDGFRB, KIT, BCR | Phase 2 | Chronic Myeloid Leukemia, BCR-ABL1 Positive; B Acute Lymphoblastic Leukemia; Inherited Bone Marrow Failure Syndrome | Mar 2027 |
| National Cancer Institute (NCI) | Nilotinib Tyrosine-protein kinase ABL inhibitor; Bcr/Abl fusion protein inhibitor | ABL1, BCR | Phase 2 | Neoplasms; Metastatic Malignant Solid Neoplasm | Apr 2027 |
| The Netherlands Cancer Institute | Nilotinib Tyrosine-protein kinase ABL inhibitor; Bcr/Abl fusion protein inhibitor | ABL1, BCR | Phase 2 | Cancer | Sep 2027 |
| European LeukemiaNet | nilotinib Tyrosine-protein kinase ABL inhibitor; Bcr/Abl fusion protein inhibitor | ABL1, BCR | Phase 2 | Chronic Myeloid Leukemia | Sep 2027 |
| M.D. Anderson Cancer Center | Dasatinib Bcr/Abl fusion protein inhibitor | ABL1, BCR | Phase 2 | Chronic Phase Chronic Myelogenous Leukemia; Chronic Myeloid Leukemia; Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Advanced Malignant Solid Neoplasm | Oct 2027 |
| Centre Leon Berard | Nilotinib Tyrosine-protein kinase ABL inhibitor; Bcr/Abl fusion protein inhibitor | ABL1, BCR | Phase 2 | Malignant Solid Neoplasms | Jan 2028 |
| ECOG-ACRIN Cancer Research Group | Nilotinib Tyrosine-protein kinase ABL inhibitor; Bcr/Abl fusion protein inhibitor | ABL1, BCR | Phase 2 | Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Aug 2028 |
| Baylor College of Medicine | Bosutinib Tyrosine-protein kinase ABL inhibitor; Tyrosine-protein kinase SRC inhibitor; Tyrosine-protein kinase HCK inhibitor | ABL1, SRC, HCK, LYN, BCR | Phase 2 | Chronic Myeloid Leukemia | Nov 2028 |
| Baylor College of Medicine | Nilotinib Tyrosine-protein kinase ABL inhibitor; Bcr/Abl fusion protein inhibitor | ABL1, BCR | Phase 2 | Chronic Myeloid Leukemia | Nov 2028 |
| Masaryk University | Nilotinib Tyrosine-protein kinase ABL inhibitor; Bcr/Abl fusion protein inhibitor | ABL1, BCR | Phase 2 | Chronic Myeloid Leukemia, Chronic Phase | – |
| Otsuka | Ponatinib Bcr/Abl fusion protein inhibitor | ABL1, BCR | Phase 2 | Chronic Myeloid Leukemia | – |
| Taiho Pharmaceutical | Imatinib Tyrosine-protein kinase ABL inhibitor; Platelet-derived growth factor receptor beta inhibitor; Stem cell growth factor receptor inhibitor | ABL1, PDGFRB, KIT, BCR | Phase 1 | Gastrointestinal Stromal Tumors; Hematological Neoplasms; Tyrosine Kinase Inhibitors; Leukemia, Acute Lymphoblastic … | Dec 2026 |
| Enliven Therapeutics | ELVN-001 Third-generation BCR-ABL tyrosine kinase inhibitor effective against T315I mutation | BCR, ABL1 | Phase 1 | Chronic Myeloid Leukemia; CML (Chronic Myelogenous Leukemia) | Dec 2027 |
| Incyte Biosciences International Sàrl | Ponatinib Bcr/Abl fusion protein inhibitor | ABL1, BCR | Phase 1 | Acute Myeloid Leukemia | Feb 2028 |
| Rina Plattner | Nilotinib Tyrosine-protein kinase ABL inhibitor; Bcr/Abl fusion protein inhibitor | ABL1, BCR | Phase 1 | Metastatic Melanoma | Jul 2028 |
| Children's Oncology Group | Bosutinib Tyrosine-protein kinase ABL inhibitor; Tyrosine-protein kinase SRC inhibitor; Tyrosine-protein kinase HCK inhibitor | ABL1, SRC, HCK, LYN, BCR | Phase 1 | Philadelphia Chromosome Positive CML | Jul 2028 |
| Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | MK-4208 (TERN-701) ABL kinase inhibitor | BCR, ABL1 | Phase 1 | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Nov 2029 |
Chronic Myeloid Leukemia (10) Chronic Myeloid Leukemia, Chronic Phase (6) Acute Lymphoblastic Leukemia (5) Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (3) B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 (3) Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (3) Gastrointestinal Stromal Tumors (3) Philadelphia Chromosome Positive CML (2) Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (2) Chronic Myelogenous Leukemia (2) Chronic Myeloid Leukemia (CML) (2) Chronic Phase Chronic Myelogenous Leukemia (2)
small molecule (11), mixed (8), other (3)
National Cancer Institute (NCI) (3) Baylor College of Medicine (2) Ascentage Pharma Group (1) Il-Yang Pharm. (1) Takeda (1) Incyte Biosciences International Sàrl (1) Enliven Therapeutics (1) Novartis (1) M.D. Anderson Cancer Center (1) Taiho Pharmaceutical (1) Masaryk University (1) ECOG-ACRIN Cancer Research Group (1) Rina Plattner (1) European LeukemiaNet (1) The Netherlands Cancer Institute (1) Children's Oncology Group (1) Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1) Centre Leon Berard (1) Otsuka (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.